Investors

investors

Like all industries, healthcare can benefit hugely from innovations in technology

Recuperation of healthcare costs, operational efficiencies and improved diagnoses and care to provide better quality of life for patients are just some of the benefits technology can provide.

iTP Biomedica’s state-of-the-art molecular technology tools enable unprecedented speed and accuracy in properly diagnosing cancer and other complex diseases, so clinicians can outline the proper course of action for dealing with the disease.

Pipeline

Bladder Cancer Diagnostics

iTP is initially focusing on commercializing diagnostic tools for bladder cancer.

  • Bladder cancer is the only cancer with decreasing 5-year survival.
  • Bladder cancer is the fifth most common cancer that receives the least amount of attention and research funding, and there is a major unmet need for more accurate diagnostic tools.
  • Approximately 70% of bladder cancer patients present with non-muscle invasive disease. Of these, 70% are originally diagnosed as low grade and indolent, while 30% are High Grade with a subset at risk of progressing to invasive disease. Using classical histopathology, uro-pathologists may have a difficult time telling High Grade from Low Grade disease and predicting which high grade diseases are at risk of progressing has been difficult.

Dr Alexandre Zlotta, Professor of Urology, Uro-surgeon and iTP Chief Medical Officer, discusses the need for molecular tests to manage early stage bladder cancer

BladderPredict™

Using integrative analyses of whole transcriptome derived from tissue biopsy samples, iTP classifies bladder cancer patients into three risk categories; low risk, intermediate risk and high risk. BladderPredict™ is thus the first molecular diagnostic of its kind that will assist uro-oncologists and pathologists in accurately defining the severity of non-muscle invasive cancer tumours. This greatly assists physicians in selecting optimized treatment strategies for individual patients.

BladderProgress™ – Bacillus Calmette-Guerin Treatment

Bacillus Calmette-Guerin (BCG) treatment is widely used in non-invasive bladder cancer in North America. However, progression to serious muscle-invasive disease is still observed in 30% of patients post-BCG treatment. iTP’s product, BladderProgress™ will help to more accurately predict the outcome of BCG Treatment for the individual patient.

Prostate Cancer, Colorectal Cancer and Kidney Fibrosis

iTP is currently developing whole transcriptome fingerprints to predict the risk of progression in prostate cancer, colorectal cancer and kidney fibrosis.  Kidney fibrosis is a major health problem associated with diabetes.

Blood and Urine-based Test Development

The company is developing a portfolio of blood- and urine-based diagnostic tests based on transcriptomic analysis of exosomes and circulating tumour cells (CTCs) for multiple diseases.

For information on investment opportunities that will change the face of cancer diagnoses and care globally, please contact Ken Hughes, Chief Executive Officer at 416.702.1187 or by emailing hughes@itpbiomedica.com.

Milestones at a Glance

2016

  • BladderPredict™ made available for purchase through ITP Biomedica and for distribution through Mount Sinai Services Inc.
  • iTP Biomedica receives College of American Pathologists (CAP) Laboratory Accreditation and the CLIA (Clinical Laboratory Improvement Act) certification, allowing products to be marketed across North America.
  • BladderProgress™ being developed to better predict which patients with non-muscle invasive high grade tumours will respond to front line treatment (BCG – Bacillus Calmette-Guerin).

2015

  • BladderPredict™ developed to provide a molecular classifier of non-muscle invasive bladder cancer.
  • Funding received from the Government of Ontario’s OCE’s Market Readiness CC (MRII) program.
  • iTP Biomedica and its clinical laboratory supplier and major investor, Mount Sinai Services Inc., receive ISO15189 accreditation allowing iTP products to support clinicians and patients worldwide.

2014

  • iTP Biomedica established and initially funded by Mount Sinai Hospital’s Lunenfield-Tanenbaum Research Institute (LTRI) and by Mount Sinai Services, both world renowned for cancer diagnoses and care.
  • Leadership team established.
  • Bladder Cancer targeted as first indication given unmet medical need.

 

ITP Biomedica Differentiators

 

INNOVATIVE
Innovative, state-of-the-art laboratory practices. Technology platform examines massive datasets, allowing for unprecedented depth in understanding disease.

TRANSFERABLE
Diagnostic approach is rapidly transferable to multiple cancers and complex diseases.

WORLD RENOWNED
Championed by Mount Sinai Hospital’s Lunenfield-Tanenbaum Research Institute (LTRI), world renowned for cancer diagnosis and care.

GLOBAL REACH
Laboratory, operating out of Mount Sinai Services, is one of the few Canadian medical laboratories with global reach.

EXPERTISE
Leadership team with global business experience, expertise in transcriptomics, analyzing clinical data sets and research excellence.

Our Partners

partners-msspartners-obiopartners-ltpartners-ocoe

Contact iTP: Ken Hughes - hughes@itpbiomedica.com - (416) 702-1187